Drug intelligence / Profile preview

SmofKabiven extra Nitrogen

Development stage
Phase 3
Lead developer
Fresenius Kabi
Administration
Intravenous
01

Overview

**SmofKabiven extra Nitrogen** is a three-chamber bag emulsion for intravenous parenteral nutrition, containing a lipid mixture (soybean oil, medium-chain triglycerides, olive oil, fish oil), glucose, and a high concentration of amino acids designed for patients with elevated nitrogen needs. It provides a balanced supply of energy (from lipids and glucose), proteins (amino acids delivering up to 0.28 g nitrogen/kg/day at maximum dose), and essential fatty acids including omega-3s, without electrolytes in some formulations, for use when oral or enteral nutrition is impossible, insufficient, or contraindicated. Administered via central vein over 12-24 hours, it supports adults, adolescents (12-18 years), children ≥2 years, and geriatrics, with dosing tailored to body weight, metabolic stress, and clinical condition (max 31-35 ml/kg/day). Developed and manufactured by Fresenius Kabi, it improves fatty acid profiles compared to standard lipid emulsions in pediatric studies and is evaluated in critical illness for achieving protein targets[1][2][7][12][15].

Brand names
SmofKabiven extra Nitrogen
Other names
SMOFKABIVEN EXTRA NITROGENSmofKabiven® extra Nitrogen
02

Targets

FFAR4 (Free fatty acid receptor 4)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on SmofKabiven extra Nitrogen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SmofKabiven extra Nitrogen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call